Watch AMLX. Know when insiders buy.
One email the day a filing lands. Free.
AMLX
Amylyx Pharmaceuticals, Inc.
34.10
+0.14 +0.41%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.8BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$152.1MNET CASH —52W 10.44 – 39.66SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$45.7M | −$43.4M | — | -0.39 | −$31.4M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$43.8M | −$41.3M | — | -0.37 | −$36.9M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$36.6M | −$33M | — | -0.28 | −$27.9M | $86K | −$28M | Mar 3 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$36M | −$34.4M | — | -0.37 | −$30.4M | $24K | −$30.4M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | — | — | −$42.9M | −$41.4M | — | -0.46 | −$25.2M | $17K | −$25.3M | Aug 6 |
| Q1 2025 · Mar 31 | $0 | −100.0% | — | −$37.8M | −$35.9M | — | -0.42 | −$39.8M | $11K | −$39.8M | Aug 6 |
| Q4 2024 · Dec 31derived | −$665K | −100.6% | 100.0% | −$40.7M | −$37.5M | −893.6% | -0.54 | −$59M | $20K | −$59M | Mar 3 |
| Q3 2024 · Sep 30 | $416K | −99.6% | 100.0% | −$75.7M | −$72.7M | −448.0% | -1.07 | −$41.6M | −$19K | −$41.6M | Nov 6 |
| Q2 2024 · Jun 30 | −$1M | — | 100.8% | −$76.3M | −$72.7M | — | -1.07 | −$66.6M | $89K | −$66.7M | Nov 6 |
| Q1 2024 · Mar 31 | $88.6M | — | 93.3% | −$122.1M | −$118.8M | — | -1.75 | −$489K | $67K | −$556K | Nov 6 |
| Q4 2023 · Dec 31derived | $108.4M | — | 91.4% | $1.9M | $4.7M | — | 0.07 | $13.6M | $356K | $13.2M | Mar 4 |
| Q3 2023 · Sep 30 | $102.7M | — | 94.9% | $18.7M | $20.9M | — | 0.30 | −$5.2M | $357K | −$5.5M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$153.3M | −$144.7M | — | -1.53 | −$123.3M | $138K | −$123.5M | — | — |
| FY2024 · to Dec 31 | $87.4M | 93.2% | −$314.7M | −$301.7M | -345.4% | -4.43 | −$167.6M | $157K | −$167.8M | — | — |
| FY2023 · to Dec 31 | $380.8M | 93.3% | $38.8M | $49.3M | 12.9% | 0.70 | $11.9M | $1.2M | $10.7M | — | — |
| FY2022 · to Dec 31 | $22.2M | 86.5% | −$201.3M | −$198.4M | -892.4% | -3.39 | −$179.9M | $2.5M | −$182.4M | — | — |
| FY2021 · to Dec 31 | $285K | — | −$82.7M | −$87.9M | -30853.0% | -13.35 | −$74.8M | $353K | −$75.2M | — | — |
Every number comes from Amylyx Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.